|Bid||67.00 x 300000|
|Ask||67.50 x 300000|
|Day's range||64.50 - 65.50|
|52-week range||21.38 - 71.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
One thing we could say about the analysts on Prothena Corporation plc ( NASDAQ:PRTA ) - they aren't optimistic, having...
Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.
Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.
Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.
Market forces rained on the parade of Prothena Corporation plc ( NASDAQ:PRTA ) shareholders today, when the analysts...
Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.
Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.
Prothena ( NASDAQ:PRTA ) Third Quarter 2022 Results Key Financial Results Net loss: US$45.8m (down by 142% from...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.
Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.
Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. ET on Wednesday. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. The news also propelled two stocks of other drugmakers developing Alzheimer's disease drugs significantly higher.
Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.
Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
With its stock down 30% over the past three months, it is easy to disregard Prothena (NASDAQ:PRTA). However, a closer...
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.